Brooks Lab.

BROOKS03 May 2024

Pharmaceuticals

₹

-2.10 (-1.99%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Brooks Lab.

Brooks Lab.

Pharmaceuticals

BROOKS03 May 2024

₹

-2.10 (-1.99%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date	Ratio
18-Jul-2023	R	1:16 Rights Issues of Equity Shares Trading Members of the Exchange are hereby informed that BROOKS LABORATORIES LIMITED has fixed Record Date for the purpose of Rights Issue of Equity Shares of the Company. The transactions in the Equity Shares of the Company should be done on Ex-Rights Basis with effect from the under mentioned date :- DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME & CODE BROOKS LABORATORIES LIMITED (533543) RECORD DATE 28/07/2023 PURPOSE Issue of 1 (One) Equity Share of Rs.10/- each for cash at a Premium of Rs. 65/- per Share on Rights Basis for every 16 (Sixteen) Equity Shares held.* Ex-Right basis from Date & Sett. No. 28/07/2023 DR-581/2023-2024 *As per Terms of Payment : Issue Price of Rs.75/- - Full amount to be paid on the day of Application Trading Members of the Exchange are requested to take note of it. (As Per BSE Notice Dated on 25.07.2023)	28-Jul-2023	1:16
31-Jan-2020	R	9:20 Rights Issue of Equity Shares Trading Members of the Exchange are hereby informed that, Brooks Laboratories Limited has fixed the Record date for the purpose of Rights Issue of Equity Shares. The transactions in the equity shares of the Company should be done on ex-rights basis with effect from the under mentioned date. DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME & CODE Brooks Laboratories Limited (533543) RECORD DATE 12.02.2020 PURPOSE Issue of 9 (Nine) equity shares of Rs. 20/- each on rights basis for cash at premium of Rs.10/- per share for every 20 (Twenty) equity shares held. Ex-Right basis from Date & Sett. No. 11/02/2020 DR-216/2019-2020 Trading Members of the Exchange are requested to take note of it. (As Per BSE Notice Dated on 03.02.2020)	12-Feb-2020	9:20
24-Jan-2024	BC	BROOKS LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 inter alia to consider and approve the unaudited standalone and consolida	31-Jan-2024
16-Jan-2024	BC	BROOKS LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2024 inter alia to consider and approve fund raising through Rights issue.	24-Jan-2024
31-Oct-2023	BC	BROOKS LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve the unaudited standalone and consolida	09-Nov-2023
30-Aug-2023	BC	Reg. 34 (1) Annual Report. Newspaper advertisement for conducting 21st AGM Notice of 21st AGM (As Per BSE Announcement Dated on 01/09/2023) Proceedings and Outcome of 21st AGM held on 21s	21-Sep-2023
30-Aug-2023	BC	Reg. 34 (1) Annual Report.	15-Sep-2023

Record Date01 Jan'1900

Ex-Rights Date01 Jan'1900

Premium(Rs.)65

Ratio1:16

Record Date01 Jan'1900

Ex-Rights Date01 Jan'1900

Premium(Rs.)10

Ratio9:20

Book Closure

Record Date	Split Date	Purpose
31-Jan-2024	-	BROOKS LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 inter alia to consider and approve the unaudited standalone and consolida
24-Jan-2024	-	BROOKS LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2024 inter alia to consider and approve fund raising through Rights issue.
09-Nov-2023	-	BROOKS LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve the unaudited standalone and consolida
21-Sep-2023	-	Reg. 34 (1) Annual Report. Newspaper advertisement for conducting 21st AGM Notice of 21st AGM (As Per BSE Announcement Dated on 01/09/2023) Proceedings and Outcome of 21st AGM held on 21s
15-Sep-2023	01 Jan'1900	Reg. 34 (1) Annual Report.

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Brooks Laboratories Ltd ₹103.60(-2.10/-1.99%)	103.60	-2.10	271.92	65.50	0.00	3.96
Astrazeneca Pharma India Ltd ₹5,424.45(+90.60/1.70%)	5,424.45	+90.60	13,561.13	71.45	85.02	20.71
Bliss GVS Pharma Ltd ₹119.10(-10.10/-7.82%)	119.10	-10.10	1,246.87	56.07	18.27	1.28
Cipla Ltd ₹1,424.75(+5.20/0.37%)	1,424.75	+5.20	115,033.60	54.70	34.98	4.44
Amrutanjan Health Care Ltd ₹775.50(-11.10/-1.41%)	775.50	-11.10	2,242.02	27.78	50.95	8.56
Abbott India Ltd ₹26,144.45(-459.90/-1.73%)	26,144.45	-459.90	55,556.96	15.92	48.50	17.87

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	21.75	24.32	15.70	12.61	12.00	15.89
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	21.75	24.32	15.70	12.61	12.00	15.89
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.16	0.09	0.05	0.02	0.06	0.07
Total Income	21.90	24.41	15.76	12.63	12.06	15.96
Total Expenditure	20.65	22.60	15.68	12.73	13.48	16.16
PBIDT	1.25	1.81	0.08	-0.10	-1.41	-0.20
Interest	0.21	0.19	0.17	0.18	0.24	0.19
PBDT	1.04	1.62	-0.09	-0.28	-1.65	-0.39
Depreciation	0.43	0.44	0.44	0.44	0.43	0.43
Tax	0.03	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
Reported Profit After Tax	0.58	1.18	-0.53	-0.72	-2.08	-0.82
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	0.58	1.18	-0.53	-0.72	-2.08	-0.82

EPS (Unit Curr.)	0.23	0.46	-0.22	-0.29	-0.84	-0.33
EPS (Adj) (Unit Curr.)	0.23	0.46	-0.22	-0.29	-0.83	-0.33
Calculated EPS (Unit Curr.)	0.22	0.45	-0.22	-0.29	-0.84	-0.33
Calculated EPS (Adj) (Unit Curr.)	0.22	0.45	-0.22	-0.29	-0.83	-0.33
Calculated EPS (Ann.) (Unit Curr.)	0.88	1.80	-0.86	-1.17	-3.37	-1.33
Calculated EPS (Adj) (Ann.) (Unit Curr.)	0.88	1.80	-0.85	-1.16	-3.34	-1.32
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	26.25	26.25	24.70	24.70	24.70	24.70
Reserve & Surplus	32.08	32.08	32.08	40.30	40.30	40.30
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	5.75	7.44	0.51	-0.79	-11.75	-1.26
PBDTM(%)	4.78	6.66	-0.57	-2.22	-13.75	-2.45
PATM(%)	2.67	4.85	-3.38	-5.71	-17.33	-5.16

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	21.75	24.32	15.70	12.61	15.30	18.08
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	21.75	24.32	15.70	12.61	15.30	18.08
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.16	0.09	0.05	0.02	0.45	0.40
Total Income	21.90	24.41	15.76	12.63	15.76	18.48
Total Expenditure	25.11	25.42	19.62	16.31	23.86	27.31
PBIDT	-3.21	-1.01	-3.86	-3.68	-8.10	-8.82
Interest	0.21	0.19	0.17	0.18	0.75	0.63
PBDT	-3.42	-1.20	-4.03	-3.86	-8.85	-9.45
Depreciation	0.43	0.44	0.44	0.44	2.33	2.28
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.03	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	-1.70	-3.85
Reported Profit After Tax	-3.88	-1.64	-4.47	-4.30	-9.48	-7.88
Minority Interest After NP	0.00	0.00	0.00	0.00	-4.46	-3.19
Net Profit after Minority Interest	-3.88	-1.64	-4.47	-4.30	-5.02	-4.68

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.36	0.00
Adjusted Profit After Extra-ordinary item	-3.88	-1.64	-4.47	-4.30	-5.38	-4.68

EPS (Unit Curr.)	-1.51	-0.64	-1.81	-1.75	-2.03	-3.19
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	26.25	24.70	24.70	24.70	24.70	24.70

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	-14.76	-4.15	-24.59	-29.18	-52.94	-48.78
PBDTM(%)	-15.72	-4.93	-25.67	-30.61	-57.84	-52.27
PATM(%)	-17.84	-6.74	-28.47	-34.10	-61.96	-43.58

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	24.70	24.70	24.70	24.70	16.19	16.19
Reserves Total	32.08	40.30	39.51	73.71	88.96	98.29
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	56.78	65.00	64.21	98.41	105.15	114.48
Secured Loans	5.66	4.92	8.40	26.88	31.18	27.98
Unsecured Loans	0.85	1.05	0.00	0.76	0.00	0.00
Total Debt	6.51	5.97	8.40	27.64	31.18	27.98
Total Liabilities	63.29	70.97	72.61	126.05	136.33	142.46
APPLICATION OF FUNDS :
Gross Block	22.66	21.07	19.64	132.51	132.24	132.74
Less : Accumulated Depreciation	7.65	5.93	4.68	19.49	14.54	8.10
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	15.01	15.14	14.96	113.02	117.70	124.64
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	1.12	0.02	0.11	0.29	0.52
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	46.85	46.84	46.81	0.02	0.02	0.02
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	11.30	16.59	12.38	13.77	10.05	11.41
Sundry Debtors	12.75	15.03	9.59	15.56	11.42	10.18
Cash and Bank	1.08	1.08	0.88	1.53	3.32	1.96
Loans and Advances	2.47	4.34	2.49	7.05	6.95	7.14
Total Current Assets	27.61	37.04	25.34	37.92	31.74	30.70
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	25.79	29.61	18.00	29.53	29.64	28.78
Provisions	1.32	0.74	0.63	0.56	0.44	0.35
Total Current Liabilities	27.11	30.34	18.63	30.09	30.08	29.13
Net Current Assets	0.50	6.69	6.71	7.83	1.65	1.57
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	0.00	0.00	20.48	20.80
Deferred Tax Liability	0.00	0.00	0.00	0.00	9.56	10.06
Net Deferred Tax	0.00	0.00	0.00	0.00	10.92	10.74
Total Assets	62.36	69.79	68.50	120.98	130.58	137.50
Contingent Liabilities	19.76	24.11	20.78	20.96	20.50	1.49

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	0.08	0.06	0.40	2.50	0.65
Net Cash from Operating Activities	0.56	3.12	-0.90	-9.39	-5.05
Net Cash Used In Investing Activities	-0.40	1.12	-0.74	-2.33	1.12
Net Cash Used In Financing Activities	-0.22	-4.23	1.31	9.61	5.78
Net Inc./Dec In Cash And Cash Equivalents	-0.06	0.02	-0.33	-2.10	1.85
Cash And Cash Equivalents At End Of The Year	0.02	0.08	0.06	0.40	2.50

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

63.59%

FII Shareholding

0.00%

DII Shareholding

3.86%

Public Shareholding

32.55%

**Promoter pledged shareholding 63.59%

About Brooks Laboratories Ltd

Brooks Laboratories Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 271.92 crores. It has reported a sales of Rs. 21.75 crores and a net profit of Rs. 0.58 crores for the quarter ended December 2018. The company management includes , Rajnish Kumar Bedi,Deepak Mahajan,Sonia Gupta,Jitendra Pratap Singh,Durga Sankar Maity,Mr. Bhushan Singh Rana,JAI PRAKASH VAIDYA (Brooks Laboratories Ltd) among others.

Chairman

Registered office

Village Kishanpura,Nilagarh Road Baddi,Solan,Himachal Pradesh,174101

FAX :91-1795-236939

Background

Incorporation Year2002

Face Value₹10

Market Lot1

How to buy Brooks Lab. shares on nse?

To buy Brooks Lab. shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Brooks Lab. share price today?

The Brooks Lab. shares price on nse is Rs.103.6 today.

What is the market cap of Brooks Lab. shares on BSE ?

The company has a market capitalization of Rs.271.92Cr

What is the PE & PB ratio of Brooks Lab. shares ?

PE is 0 and PB is 3.96

What is the 52 Week High and Low of Brooks Lab. shares?

Brooks Lab. stock price high: Rs.185.15 Brooks Lab. stock price low: Rs.56.5